Health
ICU: Publication Validates Real-World Clinical Impact of QUELIMMUNE™ in Pediatric AKI
By David Bautz, PhD NASDAQ:ICU READ THE FULL ICU RESEARCH REPORT Business Update Publication in Pediatric Nephrology Highlights Real-World QUELIMMUNE Data On February 9, 2026, SeaStar Medical Holding Corp. (NASDAQ:ICU) announced the publication of post-approval clinical experience for QUELIMMUNE™ (SCD-PED) in the peer-reviewed journal Pediatric Nephrology . The article, “Early post-approval
About this update from Seastar Medical Holding Corporation
[{"type":"text","content":"By David Bautz, PhD","length":19,"tagName":"p"},{"type":"text","content":"NASDAQ:ICU","length":10,"tagName":"p"},{"type":"text","content":"READ THE FULL ICU RESEARCH REPORT","length":33,"tagName":"p"},{"type":"text","content":"Business Update","length":15,"tagName":"p"},{"type":"text","content":"Publication in Pediatric Nephrology Highlights Real-World QUELIMMUNE Data","length":73,"tagName":"p"},{"type":"text","content":"On February 9, 2026, SeaStar Medical Holding Corp. (NASDAQ:ICU) announced the publication of post-approval clinical experience for QUELIMMUNE™ (SCD-PED) in the peer-reviewed journal Pediatric Nephrology. The article, “Early post-approval experience of the selective cytopheretic device surveillance registry for pediatric AKI requiring kidney replacement therapy”, highlights early experience from the SAVE Registry (NCT06517810), a post-approval surveillance registry that is evaluating the role of QUELIMMUNE therapy in the treatment of critically ill pediatric patients with life-threatening acute kidney injury (AKI) and sepsis requiring renal replacement therapy (Goldstein et al., 2026).","length":693,"tagName":"p"},{"type":"text","content":"The manuscript included observations from the first 21 pediatric patients with AKI and sepsis requiring renal replacement therapy. Additional characteristics of the treated cohort are below, which suggest this population was at least as ill, if not more so, than those enrolled in prior registrational studies.","length":310,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"100% were mechanically ventilated","length":33,"tagName":"p"}]},{"val":[{"type":"text","content":"100% were receiving vasoactive medications","length":42,"tagName":"p"}]},{"val":[{"type":"text","content":"Median PRISM III score of 15, consistent with high predicted mortality","length":70,"tagName":"p"}]},{"val":[{"type":"text","content":"33% (7/21) treated with extracorporeal membrane oxygenation (ECMO)","length":66,"tagName":"p"}]},{"val":[{"type":"text","content":"20% (4/21) with pre-existing kidney failure or prior kidney transplant","length":70,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":281,"olType":false},{"type":"text","content":"The data showed that no device-related adverse events or infections occurred and there were no immunosuppressive effects caused by the ...